NEW YORK (GenomeWeb News) – Medicyte and Reinnervate today announced a collaboration to combine their technologies, bringing a next generation of cell-based assays to the biopharma and academic research markets.

The partnership brings together Medicyte's upcyte technology and Reinnervate's Alvetex Scaffold technologies. Upcyte are genetically engineered "upregulated" primary cells, and according to Medicyte, data suggests that upcyte hepatocytes combine the benefits of quantity — up to 2,000 vials per donor can be generated — and the quality of primary hepatocytes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."